<!DOCTYPE html>
<html lang="en">
<head>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-C02ST4Z19Y"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());
  gtag('config', 'G-C02ST4Z19Y');
</script>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Aastha Dave — Regulatory Affairs & Market Access</title>
<style>
  * { margin: 0; padding: 0; box-sizing: border-box; }
  :root {
    --navy: #1a2e44;
    --teal: #9a7a2e;
    --teal-light: #e2c97e;
    --cream: #faf6ef;
    --white: #ffffff;
    --gray: #6b7280;
    --text: #1f2937;
  }
  html { scroll-behavior: smooth; }
  body { font-family: 'Georgia', serif; color: var(--text); background: var(--white); line-height: 1.7; }

  /* NAV */
  nav {
    position: fixed; top: 0; width: 100%; z-index: 100;
    background: rgba(255,255,255,0.95); backdrop-filter: blur(8px);
    border-bottom: 1px solid #e5e7eb;
    padding: 1rem 2rem; display: flex; justify-content: space-between; align-items: center;
  }
  .nav-name { font-size: 1rem; font-weight: bold; color: var(--navy); letter-spacing: 0.05em; }
  .nav-links { display: flex; gap: 2rem; list-style: none; }
  .nav-links a { text-decoration: none; color: var(--gray); font-family: 'Arial', sans-serif; font-size: 0.85rem; letter-spacing: 0.08em; text-transform: uppercase; transition: color 0.2s; }
  .nav-links a:hover { color: var(--teal); }

  /* HERO */
  #hero {
    min-height: 100vh; background: var(--navy);
    display: flex; align-items: center; justify-content: center;
    text-align: center; padding: 6rem 2rem 4rem;
    position: relative; overflow: hidden;
  }
  .hero-content { position: relative; z-index: 1; max-width: 800px; }
  .hero-photo {
    width: 140px; height: 140px; border-radius: 50%;
    border: 3px solid var(--teal-light);
    object-fit: cover; object-position: center top;
    margin: 0 auto 1.5rem; display: block;
    box-shadow: 0 0 0 6px rgba(201,168,76,0.15);
  }
  .hero-title { font-size: clamp(2rem, 5vw, 3.5rem); color: #ffffff; line-height: 1.2; margin-bottom: 1rem; font-weight: normal; }
  .hero-sub { font-family: 'Arial', sans-serif; color: rgba(255,255,255,0.65); font-size: 0.9rem; letter-spacing: 0.05em; margin-bottom: 1.5rem; }
  .hero-tagline { color: rgba(255,255,255,0.85); font-size: 1.1rem; font-style: italic; margin-bottom: 2rem; max-width: 600px; margin-left: auto; margin-right: auto; }
  .hero-icons { display: flex; justify-content: center; gap: 2.5rem; margin-bottom: 2rem; }
  .hero-icon-item { display: flex; flex-direction: column; align-items: center; gap: 0.4rem; cursor: pointer; transition: transform 0.2s ease; }
  .hero-icon-item:hover { transform: scale(1.2); }
  .hero-icon-item svg { width: 1.5rem; height: 1.5rem; stroke: #e2c97e; fill: none; stroke-width: 1.5; stroke-linecap: round; stroke-linejoin: round; }
  .hero-icon-item span { font-family: 'Arial', sans-serif; font-size: 0.65rem; letter-spacing: 0.15em; text-transform: uppercase; color: #e2c97e; }
  .hero-cta {
    display: inline-block; border: 1px solid var(--teal-light); color: var(--teal-light);
    padding: 0.75rem 2rem; text-decoration: none; font-family: 'Arial', sans-serif;
    font-size: 0.85rem; letter-spacing: 0.1em; text-transform: uppercase; transition: all 0.3s;
  }
  .hero-cta:hover { background: var(--teal-light); color: var(--navy); }

  /* SECTIONS */
  section { padding: 5rem 2rem; }
  .container { max-width: 960px; margin: 0 auto; }
  .section-label { font-family: 'Arial', sans-serif; font-size: 0.7rem; letter-spacing: 0.25em; text-transform: uppercase; color: var(--teal); margin-bottom: 0.75rem; }
  .section-title { font-size: clamp(1.6rem, 3vw, 2.2rem); color: var(--navy); margin-bottom: 2rem; font-weight: normal; }
  .divider { width: 3rem; height: 2px; background: var(--teal); margin-bottom: 2.5rem; }

  /* ABOUT */
  #about { background: var(--cream); }
  .about-text p { margin-bottom: 1.25rem; color: var(--text); font-size: 1.05rem; }
  .about-closer { font-size: 1.1rem; font-style: italic; color: var(--navy); margin-top: 1.5rem; border-left: 3px solid var(--teal); padding-left: 1.25rem; }

  /* PORTFOLIO */
  #portfolio { background: var(--white); }
  .portfolio-section { margin-bottom: 4rem; }
  .portfolio-section-title {
    font-family: 'Arial', sans-serif; font-size: 0.85rem; letter-spacing: 0.2em; text-transform: uppercase;
    color: var(--navy); margin-bottom: 1.5rem; display: flex; align-items: center; gap: 1rem;
    font-weight: bold; border-left: 3px solid var(--teal); padding-left: 0.75rem;
  }
  .portfolio-section-title::after { content: ''; flex: 1; height: 1px; background: #e5e7eb; }

  /* ── DUAL PANEL LAYOUT ── */
  .dual-panel {
    display: grid;
    grid-template-columns: 1fr 1fr;
    gap: 0;
    border: 1px solid #e5e7eb;
    margin-bottom: 1.5rem;
    align-items: start;
  }

  .panel {
    padding: 0;
    display: flex;
    flex-direction: column;
    height: 620px;
  }

  .panel:first-child {
    border-right: 1px solid #e5e7eb;
  }

  .panel-body {
    overflow-y: auto;
    flex: 1;
  }

  /* Custom scrollbar to match brand */
  .panel-body::-webkit-scrollbar { width: 5px; }
  .panel-body::-webkit-scrollbar-track { background: #f9f9f9; }
  .panel-body::-webkit-scrollbar-thumb { background: var(--teal); border-radius: 2px; }
  .panel-body::-webkit-scrollbar-thumb:hover { background: var(--navy); }

  .panel-header {
    padding: 1rem 1.5rem 0.9rem;
    border-bottom: 1px solid #e5e7eb;
    display: flex;
    align-items: center;
    gap: 0.75rem;
    background: var(--navy);
  }

  .panel-header-icon {
    width: 1.75rem;
    height: 1.75rem;
    flex-shrink: 0;
  }
  .panel-header-icon svg {
    width: 100%;
    height: 100%;
    stroke: var(--teal-light);
    fill: none;
    stroke-width: 1.5;
    stroke-linecap: round;
    stroke-linejoin: round;
  }

  .panel-header-text {}
  .panel-header-label {
    font-family: 'Arial', sans-serif;
    font-size: 0.6rem;
    letter-spacing: 0.2em;
    text-transform: uppercase;
    color: rgba(226,201,126,0.7);
    line-height: 1;
    margin-bottom: 0.2rem;
  }
  .panel-header-title {
    font-family: 'Arial', sans-serif;
    font-size: 0.9rem;
    font-weight: 700;
    color: #ffffff;
    letter-spacing: 0.03em;
  }

  .panel-body {
    padding: 1.25rem 1.5rem;
    flex: 1;
    display: flex;
    flex-direction: column;
    gap: 1rem;
  }

  /* Panel project cards — more compact than full cards */
  .panel-card {
    border-bottom: 1px solid #f0f0f0;
    padding-bottom: 1rem;
  }
  .panel-card:last-child {
    border-bottom: none;
    padding-bottom: 0;
  }

  .panel-card h3 {
    color: var(--navy);
    font-size: 0.95rem;
    margin-bottom: 0.25rem;
    line-height: 1.35;
  }
  .panel-card .project-tags {
    font-family: 'Arial', sans-serif;
    font-size: 0.65rem;
    color: var(--teal);
    letter-spacing: 0.06em;
    text-transform: uppercase;
    margin-bottom: 0.5rem;
  }
  .panel-card p {
    color: var(--gray);
    font-size: 0.875rem;
    margin-bottom: 0.5rem;
    line-height: 1.55;
  }
  .panel-card ul {
    padding-left: 1.1rem;
    color: var(--gray);
    font-size: 0.875rem;
    margin-bottom: 0.5rem;
  }
  .panel-card ul li { margin-bottom: 0.25rem; }

  .panel-btn-row {
    display: flex;
    flex-wrap: wrap;
    gap: 0.5rem;
    margin-top: 0.4rem;
  }

  .panel-divider-label {
    font-family: 'Arial', sans-serif;
    font-size: 0.65rem;
    letter-spacing: 0.18em;
    text-transform: uppercase;
    color: var(--navy);
    font-weight: 700;
    margin: 0.5rem 0 0.75rem;
    padding-top: 0.5rem;
    border-top: 1px solid #e5e7eb;
  }

  .panel-divider-label:first-child {
    border-top: none;
    padding-top: 0;
    margin-top: 0;
  }

  /* standard project card (kept for non-regulatory sections) */
  .project-card { border: 1px solid #e5e7eb; padding: 2rem; margin-bottom: 1.5rem; transition: border-color 0.2s, box-shadow 0.2s; }
  .project-card:hover { border-color: var(--teal); box-shadow: 0 4px 20px rgba(201,168,76,0.08); }
  .project-card h3 { color: var(--navy); font-size: 1.1rem; margin-bottom: 0.4rem; }
  .project-tags { font-family: 'Arial', sans-serif; font-size: 0.72rem; color: var(--teal); letter-spacing: 0.08em; text-transform: uppercase; margin-bottom: 1rem; }
  .project-card p { color: var(--gray); font-size: 0.95rem; margin-bottom: 0.75rem; }
  .project-card ul { padding-left: 1.25rem; color: var(--gray); font-size: 0.95rem; }
  .project-card ul li { margin-bottom: 0.4rem; }
  .project-card h4 { color: var(--navy); font-size: 0.95rem; margin: 1.25rem 0 0.5rem; font-style: italic; }

  .download-btn {
    display: inline-block;
    padding: 0.4rem 1rem;
    border: 1px solid var(--teal); color: var(--teal);
    text-decoration: none; font-family: 'Arial', sans-serif;
    font-size: 0.72rem; letter-spacing: 0.07em; text-transform: uppercase; transition: all 0.2s;
  }
  .download-btn:hover { background: var(--teal); color: var(--white); }

  /* full-size download btn for non-panel cards */
  .project-card .download-btn {
    padding: 0.5rem 1.25rem;
    font-size: 0.78rem;
    margin-top: 1rem;
    margin-right: 0.75rem;
  }

  .on-request { font-family: 'Arial', sans-serif; font-size: 0.8rem; color: var(--gray); font-style: italic; margin-top: 0.75rem; }
  .in-progress { display: inline-block; background: #fef3c7; color: #92400e; font-family: 'Arial', sans-serif; font-size: 0.7rem; letter-spacing: 0.08em; text-transform: uppercase; padding: 0.2rem 0.6rem; margin-bottom: 0.75rem; }
  .no-share { font-family: 'Arial', sans-serif; font-size: 0.8rem; color: var(--gray); font-style: italic; margin-top: 0.5rem; }
  .group-label { font-family: 'Arial', sans-serif; font-size: 0.75rem; letter-spacing: 0.15em; text-transform: uppercase; color: var(--navy); margin: 2rem 0 1rem; font-weight: bold; }

  /* SKILLS */
  #skills { background: var(--navy); }
  #skills .section-title { color: var(--white); }
  #skills .section-label { color: var(--teal-light); }
  #skills .divider { background: var(--teal-light); }
  .skills-grid { display: grid; grid-template-columns: repeat(auto-fit, minmax(240px, 1fr)); gap: 1.5rem; }
  .skill-group { display: flex; flex-direction: column; gap: 0.5rem; }
  .skill-icon { width: 2rem; height: 2rem; background: rgba(201,168,76,0.15); border-radius: 50%; display: flex; align-items: center; justify-content: center; margin-bottom: 0.25rem; }
  .skill-icon svg { width: 1rem; height: 1rem; stroke: #e2c97e; fill: none; stroke-width: 2; stroke-linecap: round; stroke-linejoin: round; }
  .skill-group h4 { font-family: 'Arial', sans-serif; font-size: 0.7rem; letter-spacing: 0.2em; text-transform: uppercase; color: #e2c97e; margin-bottom: 0.25rem; }
  .skill-group p { color: rgba(255,255,255,0.7); font-size: 0.9rem; line-height: 1.8; font-family: 'Arial', sans-serif; }

  /* CONTACT */
  #contact { background: var(--cream); text-align: center; }
  #contact .section-title { margin-bottom: 0.75rem; }
  #contact p { color: var(--gray); margin-bottom: 2rem; font-size: 1rem; }
  .contact-links { display: flex; gap: 1rem; justify-content: center; flex-wrap: wrap; }
  .contact-link { display: inline-block; padding: 0.75rem 2rem; text-decoration: none; font-family: 'Arial', sans-serif; font-size: 0.85rem; letter-spacing: 0.1em; text-transform: uppercase; transition: all 0.2s; }
  .contact-link.primary { background: var(--navy); color: var(--white); }
  .contact-link.primary:hover { background: var(--teal); }
  .contact-link.secondary { border: 1px solid var(--navy); color: var(--navy); }
  .contact-link.secondary:hover { background: var(--navy); color: var(--white); }

  /* FOOTER */
  footer { background: var(--navy); color: rgba(255,255,255,0.4); text-align: center; padding: 1.5rem; font-family: 'Arial', sans-serif; font-size: 0.78rem; }

  /* MOBILE */
  @media (max-width: 720px) {
    .nav-links { display: none; }
    section { padding: 3.5rem 1.25rem; }
    .project-card { padding: 1.25rem; }
    .dual-panel { grid-template-columns: 1fr; }
    .panel:first-child { border-right: none; border-bottom: 1px solid #e5e7eb; }
  }
</style>
</head>
<body>

<!-- NAV -->
<nav>
  <div class="nav-name">Aastha Dave</div>
  <ul class="nav-links">
    <li><a href="#about">About</a></li>
    <li><a href="#portfolio">Work</a></li>
    <li><a href="#skills">Skills</a></li>
    <li><a href="#contact">Contact</a></li>
  </ul>
</nav>

<!-- HERO -->
<section id="hero">
  <div class="hero-content">
    <div class="hero-photo" style="background:rgba(226,201,126,0.15);display:flex;align-items:center;justify-content:center;">
      <svg width="60" height="60" viewBox="0 0 24 24" fill="none" stroke="#e2c97e" stroke-width="1" stroke-linecap="round" stroke-linejoin="round"><path d="M20 21v-2a4 4 0 00-4-4H8a4 4 0 00-4 4v2"/><circle cx="12" cy="7" r="4"/></svg>
    </div>
    <h1 class="hero-title">Aastha Dave</h1>
    <p class="hero-sub">Pharm.D. &nbsp;|&nbsp; MS Regulatory Affairs Candidate</p>
    <p class="hero-tagline">Committed to doing work that makes a difference.</p>
    <div class="hero-icons">
      <div class="hero-icon-item" onclick="document.getElementById('med-affairs').scrollIntoView({behavior:'smooth'})">
        <svg viewBox="0 0 24 24"><path d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"/></svg>
        <span>Medical Affairs</span>
      </div>
      <div class="hero-icon-item" onclick="document.getElementById('reg-legal').scrollIntoView({behavior:'smooth'})">
        <svg viewBox="0 0 24 24"><path d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"/></svg>
        <span>Regulatory</span>
      </div>
      <div class="hero-icon-item" onclick="document.getElementById('market-access').scrollIntoView({behavior:'smooth'})">
        <svg viewBox="0 0 24 24"><path d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"/></svg>
        <span>Market Access</span>
      </div>
    </div>
    <a href="#about" class="hero-cta">Learn More ↓</a>
  </div>
</section>

<!-- ABOUT -->
<section id="about">
  <div class="container">
    <div class="section-label">About</div>
    <h2 class="section-title">Who I Am</h2>
    <div class="divider"></div>
    <div class="about-text">
      <p>I came to regulatory affairs the scenic route — Pharm.D. first, then consulting, then a medical affairs co-op at a global medtech company, and now finishing my MS in Regulatory Affairs at Northeastern.</p>
      <p>Along the way I realized I wanted to contribute to patient care at a different scale: not one patient at a time, but through the work that determines whether a product reaches patients at all.</p>
      <p>That clarity led me to consulting, where I spent nearly two years supporting pharma clients across multiple therapeutic areas. Consulting taught me how to be self-directed and client-facing while staying tightly connected to the broader team.</p>
      <p>At Insulet Corporation, embedded in Medical Affairs for the Omnipod® 5 franchise, I got to work in a space where patients are managing a chronic disease every single day — which made it impossible to treat the work as abstract. The co-op gave me exposure across medical, regulatory, and market access functions.</p>
      <p>Now, through my MS program, I've been building the formal regulatory foundation to sit underneath all of that experience — device submissions, quality systems, global regulatory strategy — and for my capstone I'll be taking on a market access project, which feels like the natural next piece of the puzzle.</p>
      <p class="about-closer">Medical affairs. Regulatory. Market access. Turns out, being unable to pick a lane is actually a career strategy.</p>
    </div>
  </div>
</section>

<!-- PORTFOLIO -->
<section id="portfolio">
  <div class="container">
    <div class="section-label">Portfolio</div>
    <h2 class="section-title">Selected Work</h2>
    <div class="divider"></div>

    <!-- 01 Medical Affairs -->
    <div class="portfolio-section" id="med-affairs">
      <div class="portfolio-section-title">01 — Medical Affairs</div>

      <div class="project-card">
        <h3>Medical Communications Consulting</h3>
        <div class="project-tags">Pharma | Med Comms | Multiple Therapeutic Areas</div>
        <p>Nearly two years supporting pharma clients across multiple therapeutic areas — developing and maintaining Standard Response Letters, scientific response letters, and custom medical information materials. Contributed to CME and non-CME scientific dissemination, KOL identification, speaker engagement programs, advisory board activities, and evidence gap analyses. Led end-to-end production of a scientific conference video as project lead, managing vendor deliverables, timelines, and budget from initiation through delivery.</p>
        <p class="no-share">Proprietary materials not shared.</p>
      </div>

      <div class="project-card">
        <h3>Graduate Co-op — Medical Affairs, Insulet Corporation</h3>
        <div class="project-tags">Medical Affairs | Insulet Corporation | Global</div>
        <p>Embedded within the Medical Information and Medical Communications team at Insulet Corporation. Day-to-day responsibilities included:</p>
        <ul>
          <li>Authoring and contributing to 20+ FDA SIUU-compliant Scientific Response Letters (SRLs) and custom response documents</li>
          <li>Maintaining and updating Standard Response Letters (SRLs) across global markets</li>
          <li>Built and maintained a competitive intelligence tracker spanning clinical data and study methodologies across competitor products</li>
          <li>Supporting scientific congress execution across 3 major international and multiple regional meetings</li>
          <li>Managing MLR reviews via Veeva, coordinating cross-functional review timelines</li>
          <li>Responding to internal evidence requests from cross-functional teams</li>
        </ul>
        <p class="no-share">Proprietary materials not shared.</p>
      </div>

      <div class="project-card">
        <h3>Co-op Project — Global Off-Label Inquiry Regulatory Matrix</h3>
        <div class="project-tags">Regulatory Intelligence | Global | Cross-functional</div>
        <p>Mapped off-label inquiry response regulations across U.S., Canada, Australia, EU, APAC, GCC, and LATAM into a single reference matrix. Presented findings to stakeholders across Regulatory Affairs, Medical Affairs, Market Access, and Compliance — a cross-functional discussion that led to the formalization of a global SOP and updates to internal SRL templates.</p>
        <p class="no-share">Proprietary materials not shared.</p>
      </div>

      <div class="project-card">
        <h3>Self-Initiated — AI-Assisted Insights Report</h3>
        <div class="project-tags">Medical Affairs | AI | Process Innovation</div>
        <p>Independently piloted an AI-assisted weekly insights report to automate monitoring and synthesis across multiple data sources — designed to surface relevant updates without requiring manual review of each source.</p>
        <p class="no-share">Proprietary materials not shared.</p>
      </div>
    </div>

    <!-- 02 Regulatory & Legal — DUAL PANEL -->
    <div class="portfolio-section" id="reg-legal">
      <div class="portfolio-section-title">02 — Regulatory &amp; Legal Writing</div>

      <!-- ══ DUAL PANEL ══ -->
      <div class="dual-panel">

        <!-- LEFT: Biopharmaceuticals -->
        <div class="panel">
          <div class="panel-header">
            <div class="panel-header-icon">
              <svg viewBox="0 0 24 24"><path d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"/></svg>
            </div>
            <div class="panel-header-text">
              <div class="panel-header-label">Submissions &amp; Strategy</div>
              <div class="panel-header-title">Biopharmaceuticals</div>
            </div>
          </div>

          <div class="panel-body">

            <div class="panel-divider-label">Pre-IND Package — Cromaglutide (OBEGO™)</div>

            <div class="panel-card">
              <h3>Pre-IND Meeting Package</h3>
              <div class="project-tags">Type B Meeting | 21 CFR Part 312 | RA-Authored</div>
              <p>A single combined package containing all three RA-authored Pre-IND deliverables for cromaglutide (OBEGO™):</p>
              <ul>
                <li><strong>Meeting Request Letter</strong> — Formal Type B meeting request to DMEP/CDER with drug overview, rationale for FIH entry, proposed logistics, and a structured preview of five substantive questions spanning nonclinical adequacy, thyroid C-cell findings, Phase 1 design, CMC controls, and Fast Track eligibility.</li>
                <li><strong>Briefing Document</strong> — Substantive package submitted 30 days prior to meeting. Includes executive summary, pharmacology and MoA overview, nonclinical data summary table, Phase 1 SAD/MAD design synopsis with MRSD calculation, IND-stage CMC control strategy, and five detailed questions with Sponsor positions.</li>
                <li><strong>Meeting Minutes</strong> — RA-drafted meeting record including attendee log, FDA written responses to all five questions, discussion summaries, and a consolidated action item tracker with owners and due dates. Submitted to FDA within 30 days post-meeting and finalized following FDA review.</li>
              </ul>
              <div class="panel-btn-row">
                <a href="obego-preind-materials.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-divider-label">IND — Cromaglutide (OBEGO™)</div>

            <div class="panel-card">
              <h3>Investigational New Drug (IND) Application</h3>
              <div class="project-tags">21 CFR Part 312 | eCTD | Phase 1 FIH | RA-Authored Sections</div>
              <p>Full IND package for cromaglutide (OBS-2020), a GLP-1 receptor agonist for chronic weight management. RA-authored sections include FDA Form 1571, Cover Letter, Introductory Statement, General Investigational Plan, Administrative Information, CMC Summary, FDA Forms 1572 and 3674, and Categorical Exclusion. Submitted in eCTD format per FDA Guidance Revision 8 (September 2024).</p>
              <div class="panel-btn-row">
                <a href="obego-ind.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-divider-label">NDA — Cromaglutide (OBEGO™)</div>

            <div class="panel-card">
              <h3>New Drug Application (NDA)</h3>
              <div class="project-tags">505(b)(1) | ICH M4 CTD | eCTD | RA-Authored Sections</div>
              <p>505(b)(1) NDA for cromaglutide, supported by the CERES Phase 3 clinical programme. RA-authored sections span all of Module 1 (FDA 356h, Cover Letter, full PLR-format draft package insert, patent certifications, iPSP, categorical exclusion), Module 2 summaries (Clinical Overview, Clinical Summary with pivotal efficacy and integrated safety tables), and Module 3 CMC. Non-RA modules summarised with cross-functional attribution.</p>
              <div class="panel-btn-row">
                <a href="obego-nda.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

          </div><!-- end panel-body -->
        </div><!-- end left panel -->

        <!-- RIGHT: Medical Devices -->
        <div class="panel">
          <div class="panel-header">
            <div class="panel-header-icon">
              <svg viewBox="0 0 24 24"><path d="M9 3H5a2 2 0 00-2 2v4m6-6h10a2 2 0 012 2v4M9 3v18m0 0h10a2 2 0 002-2V9M9 21H5a2 2 0 01-2-2V9m0 0h18"/></svg>
            </div>
            <div class="panel-header-text">
              <div class="panel-header-label">Submissions &amp; Strategy</div>
              <div class="panel-header-title">Medical Devices</div>
            </div>
          </div>

          <div class="panel-body">

            <div class="panel-divider-label">Submissions</div>

            <div class="panel-card">
              <h3>510(k) Premarket Notification — VascuCage™ IVC Filter</h3>
              <div class="project-tags">510(k) | 21 CFR 807.92 | Predicate Strategy | Graduate Coursework</div>
              <p>Complete 510(k) Summary establishing substantial equivalence of the VascuCage™ Inferior Vena Cava Filter to the Crux® Vena Cava Filter (K150262). Structured comparison of intended use, technological characteristics, and design differences per 21 CFR 807.92.</p>
              <div class="panel-btn-row">
                <a href="vascucage-510k.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>PMA Regulatory Strategy &amp; Global Classification — VascuCage™</h3>
              <div class="project-tags">PMA | FDA / EU MDR / Health Canada | Global Classification | Graduate Coursework</div>
              <p>Regulatory strategy document determining the appropriate U.S. PMA pathway, with parallel classification analysis across the U.S. (Class III), EU (Class III under EU MDR), and Canada (Class IV under CMDR). Includes proposed indications for use, marketing claims, and competitive device landscape.</p>
              <div class="panel-btn-row">
                <a href="vascucage-pma-strategy.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>Pre-Submission (Q-Sub) Package — StrokeMate™ AI-Enabled CT Imaging System</h3>
              <div class="project-tags">Q-Sub | AI/SaMD | 510(k) | Cybersecurity | Graduate Coursework</div>
              <p>Formal FDA Pre-Submission request for an AI-enabled CT imaging system for acute neurovascular event detection. Seeks FDA feedback on predicate strategy for AI-integrated devices, retrospective dataset validation, algorithm drift controls, and cybersecurity risk modeling for adversarial inputs and DICOM integrity threats.</p>
              <div class="panel-btn-row">
                <a href="strokemate-qsub.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>Multi-Jurisdictional PMA Strategy — nuBeam BNCT System</h3>
              <div class="project-tags">PMA | U.S. / Canada / Mexico | Combination Product | IDE | Graduate Coursework</div>
              <p>Global regulatory strategy for an accelerator-based combination product for Boron Neutron Capture Therapy. Modular PMA anchored in the U.S., with parallel Class IV MDL submission to Health Canada and Class III Registro Sanitario to COFEPRIS. Covers harmonized testing (IEC 60601, IEC 62304, ISO 14971, ISO 13485), IDE strategy, and post-market obligations across all three markets.</p>
              <div class="panel-btn-row">
                <a href="nubeam-global-strategy.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-divider-label">Quality Systems &amp; Device Development</div>

            <div class="panel-card">
              <h3>Design Control &amp; Development Plan — StrokeMate™</h3>
              <div class="project-tags">21 CFR 820.30 | Design Controls | DHF | Graduate Coursework</div>
              <p>21 CFR 820.30-aligned design and development plan covering the full device lifecycle from user needs through design transfer. Includes RACI mapping, design input/output documentation, V&amp;V strategy, ISO 14971 risk management integration, and DHF structure.</p>
              <div class="panel-btn-row">
                <a href="strokemate-design-control.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>QMS SOP Suite — Document Control | CAPA | Complaint Handling &amp; MDR</h3>
              <div class="project-tags">21 CFR 820 | ISO 13485 | CAPA | MDR Reporting | Graduate Coursework</div>
              <p>Three production-format SOPs for RadHealth, Inc., aligned with 21 CFR Part 820 and ISO 13485:2016, each with purpose, scope, definitions, RACI matrix, step-by-step procedures, and revision history. The CAPA and Complaint Handling SOPs specifically address AI output anomalies, cybersecurity events, and MDR reportability determinations.</p>
              <div class="panel-btn-row">
                <a href="strokemate-sop-suite.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>BioDevek — Gap Analysis &amp; ISO 14971 Risk Management Plan</h3>
              <div class="project-tags">Academic-Industry Collaboration | 21 CFR 820 / ISO 13485 | Risk Management</div>
              <p>Gap analysis and ISO 14971-aligned risk management plan for an early-stage medical device startup, supporting regulatory compliance positioning and post-market surveillance readiness.</p>
              <p style="font-family:'Arial',sans-serif;font-size:0.8rem;color:var(--gray);font-style:italic;margin-top:0.4rem;">Available upon request.</p>
            </div>

            <div class="panel-divider-label">Safety &amp; Legal</div>

            <div class="panel-card">
              <h3>Post-Market Benefit-Risk Analysis — SUSVIMO® Recall</h3>
              <div class="project-tags">Benefit-Risk | Post-Market Surveillance | Combination Product | REMS | Graduate Coursework</div>
              <p>Comprehensive analysis of SUSVIMO®'s regulatory journey from BLA approval to voluntary recall — examining FDA's Benefit-Risk Framework for combination products, FAERS signal detection, REMS considerations, human factors gaps, and strategic recommendations for combination product oversight.</p>
              <div class="panel-btn-row">
                <a href="susvimo-benefit-risk.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

            <div class="panel-card">
              <h3>Harmonising Innovation: Reconciling the EU AI Act and MDR</h3>
              <div class="project-tags">Legal &amp; Policy Analysis | EU Digital Health | International RA | Graduate Coursework</div>
              <p>Examines what happens when the EU MDR and AI Act overlap without a clear hierarchy, argued through three CJEU cases. Addresses definitional ambiguity, inconsistent Notified Body enforcement, and disproportionate compliance burdens for manufacturers of AI-enabled medical devices.</p>
              <div class="panel-btn-row">
                <a href="eu-ai-act-paper.pdf" target="_blank" class="download-btn">View PDF</a>
              </div>
            </div>

          </div><!-- end panel-body -->
        </div><!-- end right panel -->

      </div><!-- end dual-panel -->
    </div><!-- end reg-legal section -->

    <!-- 03 Market Access -->
    <div class="portfolio-section" id="market-access">
      <div class="portfolio-section-title">03 — Market Access</div>

      <div class="project-card">
        <span class="in-progress">In Progress — June 2026</span>
        <h3>Capstone: Market Access Strategy — Gene Therapy Agent</h3>
        <div class="project-tags">Market Access | HEOR | Payer Evidence | Value Demonstration</div>
        <p>My capstone project applies market access and health economics frameworks to develop a payer-facing value strategy for a gene therapy agent — one of the most complex reimbursement challenges in the current landscape given the one-time, high-cost nature of these treatments. This section will be updated upon completion.</p>
        <p class="on-request">Check back June 2026.</p>
      </div>

      <div class="project-card">
        <h3>Payer Evidence &amp; Market Access Support — Insulet Corporation</h3>
        <div class="project-tags">Market Access | CMS Medicaid | Value Narratives | Payer Relations</div>
        <p>During my co-op, I partnered with the Market Access and Payer Relations teams to support CMS Medicaid coverage discussions for the Omnipod® 5 franchise. This included developing evidence mapping frameworks that translated clinical data into payer-relevant value narratives — connecting the clinical evidence base to the language and criteria that actually drive coverage decisions.</p>
        <p class="no-share">Proprietary materials not shared.</p>
      </div>
    </div>

  </div>
</section>

<!-- SKILLS -->
<section id="skills">
  <div class="container">
    <div class="section-label">Capabilities</div>
    <h2 class="section-title">Skills &amp; Tools</h2>
    <div class="divider"></div>
    <div class="skills-grid">
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M9 12h6m-6 4h6m2 5H7a2 2 0 01-2-2V5a2 2 0 012-2h5.586a1 1 0 01.707.293l5.414 5.414a1 1 0 01.293.707V19a2 2 0 01-2 2z"/></svg></div>
        <h4>Regulatory</h4>
        <p>510(k) · PMA · Q-Sub · SaMD · Global Classification · FDA · EU MDR · Health Canada · COFEPRIS</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M9 5H7a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V7a2 2 0 00-2-2h-2M9 5a2 2 0 002 2h2a2 2 0 002-2M9 5a2 2 0 012-2h2a2 2 0 012 2m-6 9l2 2 4-4"/></svg></div>
        <h4>Quality Systems</h4>
        <p>21 CFR 820 · ISO 13485 · ISO 14971 · CAPA · Complaint Handling · MDR Reporting</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M19.428 15.428a2 2 0 00-1.022-.547l-2.387-.477a6 6 0 00-3.86.517l-.318.158a6 6 0 01-3.86.517L6.05 15.21a2 2 0 00-1.806.547M8 4h8l-1 1v5.172a2 2 0 00.586 1.414l5 5c1.26 1.26.367 3.414-1.415 3.414H4.828c-1.782 0-2.674-2.154-1.414-3.414l5-5A2 2 0 009 10.172V5L8 4z"/></svg></div>
        <h4>Medical Affairs</h4>
        <p>Scientific Response Letters · SRL Lifecycle · MLR Reviews · Congress Support · Competitive Intelligence</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M9 19v-6a2 2 0 00-2-2H5a2 2 0 00-2 2v6a2 2 0 002 2h2a2 2 0 002-2zm0 0V9a2 2 0 012-2h2a2 2 0 012 2v10m-6 0a2 2 0 002 2h2a2 2 0 002-2m0 0V5a2 2 0 012-2h2a2 2 0 012 2v14a2 2 0 01-2 2h-2a2 2 0 01-2-2z"/></svg></div>
        <h4>Market Access</h4>
        <p>Payer Evidence Mapping · CMS/Medicaid · Value Narrative Development · HEOR</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M9 12l2 2 4-4m5.618-4.016A11.955 11.955 0 0112 2.944a11.955 11.955 0 01-8.618 3.04A12.02 12.02 0 003 9c0 5.591 3.824 10.29 9 11.622 5.176-1.332 9-6.03 9-11.622 0-1.042-.133-2.052-.382-3.016z"/></svg></div>
        <h4>Safety Sciences</h4>
        <p>SUSAR Reporting · Pharmacovigilance · Benefit-Risk Assessment · REMS · FAERS · ICH E2A</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M10.325 4.317c.426-1.756 2.924-1.756 3.35 0a1.724 1.724 0 002.573 1.066c1.543-.94 3.31.826 2.37 2.37a1.724 1.724 0 001.065 2.572c1.756.426 1.756 2.924 0 3.35a1.724 1.724 0 00-1.066 2.573c.94 1.543-.826 3.31-2.37 2.37a1.724 1.724 0 00-2.572 1.065c-.426 1.756-2.924 1.756-3.35 0a1.724 1.724 0 00-2.573-1.066c-1.543.94-3.31-.826-2.37-2.37a1.724 1.724 0 00-1.065-2.572c-1.756-.426-1.756-2.924 0-3.35a1.724 1.724 0 001.066-2.573c-.94-1.543.826-3.31 2.37-2.37.996.608 2.296.07 2.572-1.065z"/><path d="M15 12a3 3 0 11-6 0 3 3 0 016 0z"/></svg></div>
        <h4>Tools</h4>
        <p>Veeva · Microsoft Office Suite · SharePoint · Google Workspace</p>
      </div>
      <div class="skill-group">
        <div class="skill-icon"><svg viewBox="0 0 24 24"><path d="M3 5h12M9 3v2m1.048 9.5A18.022 18.022 0 016.412 9m6.088 9h7M11 21l5-10 5 10M12.751 5C11.783 10.77 8.07 15.61 3 18.129"/></svg></div>
        <h4>Languages</h4>
        <p>English · Hindi · Gujarati</p>
      </div>
    </div>
  </div>
</section>

<!-- CONTACT -->
<section id="contact">
  <div class="container">
    <div class="section-label">Contact</div>
    <h2 class="section-title">Let's Connect</h2>
    <div class="divider" style="margin: 0 auto 1.5rem;"></div>
    <p>Open to full-time opportunities in regulatory affairs, medical affairs, and market access.</p>
    <div class="contact-links">
      <a href="https://linkedin.com/in/aastha-dave-85547823a" target="_blank" class="contact-link primary">LinkedIn</a>
      <a href="mailto:dave.aas@northeastern.edu" class="contact-link secondary">Email Me</a>
    </div>
  </div>
</section>

<footer>
  <p>© 2026 Aastha Dave · Built with purpose, not a template.</p>
</footer>

</body>
</html>
